The Latest Breaking News from Guggenheim

Judging by his time with the Los Angeles Dodgers, Boehly will sanction big spending as long as he sees even bigger returns

SVB Leerink is initiating coverage of HilleVax Inc (NASDAQ:HLVX) shares with an Outperform rating and a $30 price target.  The analyst believes the company’s potentially first-in-class infant norovirus vaccine HIL214 represents a uniquely de-risked opportunity.  It estimates $625 million in risk-adjusted infant HIL214 sales in 2030E ($1 billion unadjusted).  The outlook is supported by…

Guggenheim has decided to maintain its Buy rating of Albertsons Companies (NYSE:ACI) and raise its price target from $34.00 to $37.00. Shares of Albertsons Companies are trading up 4.41% over the last 24 hours, at $33.38 per share.

Guggenheim has decided to maintain its Buy rating of Rubius Therapeutics (NASDAQ:RUBY) and lower its price target from $25.00 to $5.00. Shares of Rubius Therapeutics are trading down 24.14% over the last 24 hours, at $2.42 per share.

Teladoc Health Inc (NYSE: TDOC) is a market leader in digital services, and the breadth of its services is unmatched, according to Guggenheim. The Teladoc Health Analyst: Sandy Draper initiated coverage of Teladoc Health with a Buy rating and $96 price target.

Upgrades

Upgrades

ESS Tech Inc (NYSE:GWH) coverage has been initiated with a Buy rating and a price target of $10 (implying an upside of 82.5%) by Guggenheim analyst Joseph Osha. The analyst cites ESS as one of a large group of companies over the past two decades aiming to make flow batteries work commercially. Osha views ESS…

Upgrades